Inside the Diagnostics Industry: Ambry Genetics Leading the Way With Clinical Next-Generation Sequencing

In early March, Ambry Genetics (Aliso Viejo, Calif.) reached the milestone of having sequenced 10,000 clinical diagnostic samples with next-generation sequencing (NGS) and processed 100,000 total NGS samples. Ambry has a proud history of being on the forefront of genetic testing, having been among the first purchasers of commercially available sequencing instruments back in 2007. The company says it was the first to offer an NGS-based diagnostic test in April 2010, with the introduction of its 81-gene panel for X-linked intellectual disability. Ambry continued with its list of firsts by launching the first clinically available whole-exome sequencing test at a CLIA-certified laboratory in 2011. Evolving from its roots in cystic fibrosis (CF) testing, Ambry continues to develop and enhance its comprehensive testing menu with significant investments in automation. This has allowed the company to focus on reducing test turnaround time while retaining its focus on quality client service and steadfast attention to their guiding ethical principles. Recently, Ambry CEO Charles Dunlop and Ardy Arianpour, Ambry’s vice president of business development, spoke to DTTR about the evolution of NGS in clinical care and Ambry’s commitment to rapid, yet responsible, growth in the future. Ambry Genetics has been a leader in clinically […]